Belzutifan Gets Priority Review for Advanced Renal Cell Carcinoma
The FDA has accepted for priority review the supplemental new drug application for belzutifan to treat adults with advanced renal cell carcinoma who previously received immune checkpoint and anti-angiogenic therapies.